Role of inflammatory cytokines in COVID-19 patients: A review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to …
AA Rabaan, SH Al-Ahmed, J Muhammad, A Khan… - Vaccines, 2021 - mdpi.com
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), is a severe pandemic of the current century. The vicious …
coronavirus 2 (SARS-CoV-2), is a severe pandemic of the current century. The vicious …
Mesenchymal stem cell therapy for severe COVID-19
L Shi, L Wang, R Xu, C Zhang, Y Xie, K Liu… - Signal transduction and …, 2021 - nature.com
Abstract The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has placed a global public burden on health …
syndrome coronavirus 2 (SARS-CoV-2), has placed a global public burden on health …
[HTML][HTML] Mesenchymal stem cell treatment for COVID-19
R Xu, Z Feng, FS Wang - EBioMedicine, 2022 - thelancet.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused a
global pandemic since late 2019 that resulted in more than 360 million population infection …
global pandemic since late 2019 that resulted in more than 360 million population infection …
Diverse immunological factors influencing pathogenesis in patients with COVID-19: a review on viral dissemination, immunotherapeutic options to counter cytokine …
AA Rabaan, SH Al-Ahmed, MA Garout, AM Al-Qaaneh… - Pathogens, 2021 - mdpi.com
The pathogenesis of coronavirus disease 2019 (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), is still not fully unraveled. Though …
respiratory syndrome coronavirus 2 (SARS-CoV-2), is still not fully unraveled. Though …
SARS-CoV-2 infection and lung regeneration
F Zhao, Q Ma, Q Yue, H Chen - Clinical Microbiology Reviews, 2022 - Am Soc Microbiol
The lung is the primary site of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2)-induced immunopathology whereby the virus enters the host cells by binding to …
2)-induced immunopathology whereby the virus enters the host cells by binding to …
Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19
S Yasamineh, HG Kalajahi, P Yasamineh… - Stem Cell Research & …, 2022 - Springer
The SARS-COV-2 virus has infected the world at a very high rate by causing COVID-19
disease. Nearly 507 million individuals have been infected with this virus, with …
disease. Nearly 507 million individuals have been infected with this virus, with …
Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial
L Shi, X Yuan, W Yao, S Wang, C Zhang, B Zhang… - …, 2022 - thelancet.com
Background The long-term consequences of human umbilical cord-derived mesenchymal
stem cell (UC-MSC) treatment for COVID-19 patients are yet to be reported. This study …
stem cell (UC-MSC) treatment for COVID-19 patients are yet to be reported. This study …
Bone marrow-derived mesenchymal stromal cell therapy in severe COVID-19: preliminary results of a phase I/II clinical trial
C Grégoire, N Layios, B Lambermont… - Frontiers in …, 2022 - frontiersin.org
Background Treatment of acute respiratory distress syndrome (ARDS) associated with
COronaVIrus Disease-2019 (COVID-19) currently relies on dexamethasone and supportive …
COronaVIrus Disease-2019 (COVID-19) currently relies on dexamethasone and supportive …
Updated living systematic review and meta-analysis of controlled trials of mesenchymal stromal cells to treat COVID-19: a Framework for Accelerated Synthesis of Trial …
AM Kirkham, AJM Bailey, M Monaghan… - Stem cells …, 2022 - academic.oup.com
Abstract Background Mesenchymal stromal cells (MSCs) may reduce mortality in patients
with COVID-19; however, early evidence is based on few studies with marked interstudy …
with COVID-19; however, early evidence is based on few studies with marked interstudy …
Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and …
PS Couto, N Al-Arawe, IS Filgueiras… - Frontiers in …, 2023 - frontiersin.org
During the pandemic of severe respiratory distress syndrome coronavirus 2 (SARS-CoV2),
many novel therapeutic modalities to treat Coronavirus 2019 induced disease (COVID-19) …
many novel therapeutic modalities to treat Coronavirus 2019 induced disease (COVID-19) …